Pazopanib

For research use only. Not for use in humans.

製品コードS3012 別名:GW786034

Pazopanib化学構造

分子量(MW):437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

サイズ 価格(税別) 在庫  
JPY 13600 あり
JPY 36800 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(31)

製品安全説明書

VEGFR阻害剤の選択性比較

生物活性

製品説明 Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
ターゲット
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
体外試験

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell Mo[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn[0TY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIHnjOVA:Oi56OXWtNFUh|ryP MnzlV2FPT0WU
human AN3-CA cell NYTrNoZyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWewXmllUW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yNTDuUS=> NE[xNHhUSU6JRWK=
human CGTH-W-1 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFAvODFibl2= MXnTRW5ITVJ?
human GDM-1 cell NETZNlZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGntOItKdmirYnn0bY9vKG:oIHj1cYFvKEeGTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVA{Njl7IH7N MnnxV2FPT0WU
human A204 cell MmnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGrm[lNKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFkvODZibl2= MorVV2FPT0WU
human G-402 cell NFXpS3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYrJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUOxMlg1KG6P Mof3V2FPT0WU
human MFE-296 cell NV:2T5l4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnPpTY5pcWKrdHnvckBw\iCqdX3hckBOTkVvMkm2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42QTB{MjFOwG0> M3faS3NCVkeHUh?=
human NOS-1 cell NGnRSYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mm\pTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBq[zVyPUCuOlU6QDdizszN MlPqV2FPT0WU
human KG-1 cell M1jZRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPpVpVjUW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OTd3NTFOwG0> NIrrNYxUSU6JRWK=
human HT55 cell M3rLWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmfZTY5pcWKrdHnvckBw\iCqdX3hckBJXDV3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFc5OSEQvF2= MX7TRW5ITVJ?
human MG-63 cell MmLqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVzJcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wNFE1PiEQvF2= MoLkV2FPT0WU
human CCF-STTG1 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGNETi2VVGTHNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:OS5yNEm4NUDPxE1? NFO1[YlUSU6JRWK=
human RT-112 cell M{C4WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3WwNWlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yODN5NjFOwG0> MVPTRW5ITVJ?
human MC-IXC cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYiyPFF5UW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFzNUGyJO69VQ>? NGHidpRUSU6JRWK=
human HUTU-80 cell MkfMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEHpdJVKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ6MUCzJO69VQ>? Mkn4V2FPT0WU
human MV-4-11 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEGwTVdKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjN2NUCxJO69VQ>? MnvVV2FPT0WU
human LCLC-103H cell NET2PVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWTJcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvMUCzTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 NXK4[JdOW0GQR1XS
human G-401 cell Mnr3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEX0Z2NKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PjR{MTFOwG0> NUXISHpoW0GQR1XS
human A704 cell NX:3bpBJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYDpZoRXUW6qaXLpeIlwdiCxZjDoeY1idiCDN{C0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43ODN{MzFOwG0> NFLMS2FUSU6JRWK=
human ESS-1 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVvJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFM6PiEQvF2= MoLxV2FPT0WU
human HLE cell NH7IPW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkO4NFQh|ryP MYfTRW5ITVJ?
human NY cell MkW2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn;oTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwOES4NlEh|ryP Mn\VV2FPT0WU
human A427 cell NIjLRZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIfvPFlKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk5ODd3IN88US=> MX3TRW5ITVJ?
human SK-N-DZ cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGPGXWNKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB{M{ixJO69VQ>? MkX6V2FPT0WU
human J82 cell MmL1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWLodpREUW6qaXLpeIlwdiCxZjDoeY1idiCMOEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA3ODh6IN88US=> NX3kSItrW0GQR1XS
human GI-1 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYXJcohq[mm2aX;uJI9nKGi3bXHuJGdKNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKyPVUyKM7:TR?= MVvTRW5ITVJ?
human NCI-H716 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXfaO4RoUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFcyPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwM{G2N|Mh|ryP M4j0UXNCVkeHUh?=
human SF126 cell Ml3MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUP1Omg{UW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDd2NUmg{txO M{f3e3NCVkeHUh?=
human H4 cell MmPFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYDJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53MUK2NkDPxE1? NGC4WYtUSU6JRWK=
human LB831-BLC cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnTaTY5pcWKrdHnvckBw\iCqdX3hckBNSjh|MT3CUGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV2NU[2JO69VQ>? NWXnfGVGW0GQR1XS
human HCC1395 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHT6OVBKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GzPVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV6MUW2JO69VQ>? NXqxVoN{W0GQR1XS
human LK-2 cell M1K2fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnnBTY5pcWKrdHnvckBw\iCqdX3hckBNUy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj62OFU3QSEQvF2= MXXTRW5ITVJ?
human G-361 cell M{\4Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWHJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6wOFA5OiEQvF2= NXzrU4tSW0GQR1XS
human NCI-H2342 cell NVy2Zlc4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEDqeZlKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlM1OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LjDJR|UxRTNwMUOzNVYh|ryP M4HoOXNCVkeHUh?=
human SK-LU-1 cell  MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV65OmQ3UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zOEe2O{DPxE1? NX;KUHBoW0GQR1XS
human IGROV-1 cell  NVT0e2dFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXXaWFlXUW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5{NEexN{DPxE1? NH7HUnJUSU6JRWK=
human EB2 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVTJcohq[mm2aX;uJI9nKGi3bXHuJGVDOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMkixOlgh|ryP NWXKO5dGW0GQR1XS
human CAL-54 cell NVuyeJlnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MojDTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI5OzZ5IN88US=> Mm\vV2FPT0WU
human LB1047-RCC cell NH;MUY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE\3NmlKdmirYnn0bY9vKG:oIHj1cYFvKE:FVVKtUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOzNzM{[4JO69VQ>? M37xTHNCVkeHUh?=
Daudi cell NXvmW5NHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3n0TGlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNUOxOlQh|ryP MVPTRW5ITVJ?
human Daudi cell M2eyOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlXjTY5pcWKrdHnvckBw\iCqdX3hckBF[XWmaTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlYzOTlizszN M2XQSXNCVkeHUh?=
human A172 cell NHzIbmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1\URWlvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|M4QSEQvF2= NIrWWG5USU6JRWK=
human KGN cell Ml7mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3XzOGlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6wOlcxQSEQvF2= MUDTRW5ITVJ?
human SNG-M cell NXrCN5FJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2OweGlvcGmkaYTpc44hd2ZiaIXtZY4hW06JLV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA5PjZ7IN88US=> NV65doZzW0GQR1XS
human SW1710 cell NVHl[GtXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWHLbmRHUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR5M{G4JO69VQ>? MWPTRW5ITVJ?
human HT29 cells NYHBSVFkWHKxbHnm[ZJifGmxbjDhd5NigQ>? NWP4TYtFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFI6KGOnbHzzJIlvKHOncoXtJINwdnSjaX7pcochdWWmaYXt M3vyRlE5PjJyM{iy
human A375P cells NHvBdW1Rem:uaX\ldoF1cW:wIHHzd4F6 M4jYZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OXAh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= MVKxPFYzODN6Mh?=
human HN5 cells NEPYRYhRem:uaX\ldoF1cW:wIHHzd4F6 NWG0fZRNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUlUh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= NHf0T4oyQDZ{MEO4Ni=>
HUVEC NIn1VG5HfW6ldHnvckBie3OjeR?= NIHWb48yKM7:TR?= M1zQOFYhcA>? MVHBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;uJIF1KDBwMTD1UUBi\nSncjC2JIhzeyCkeTDNZZRzcWenbDDhd5NigQ>? NV3HNlZuOjRyM{[wOFI>
human Daoy cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3vEemlvcGmkaYTpc44hd2ZiaIXtZY4hTGGxeTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuO|c6PDlizszN NVv2OW1LW0GQR1XS
human DMS-273 cell M2\6SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWPJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk3OjB{IN88US=> NYD1UYZ4W0GQR1XS
human KU812 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnXhTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|c5OTJizszN MVXTRW5ITVJ?
human NCI-H727 cell NIS2bmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWXZWoRSUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFczPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNEC5NFEh|ryP MknDV2FPT0WU
human P30-OHK cell MlTDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWrJcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ3QTRizszN NVLrWXFtW0GQR1XS
human MIA-PaCa-2 cell NGPEUIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXvJcohq[mm2aX;uJI9nKGi3bXHuJG1KSS2SYVPhMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjZyNE[2JO69VQ>? NXT0[G5bW0GQR1XS
human TT cell MkGzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEfQc2NKdmirYnn0bY9vKG:oIHj1cYFvKFSWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62OlI1KM7:TR?= M3i0S3NCVkeHUh?=
human DK-MG cell NXLrSJFXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MonFTY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxOjhizqzt MYLTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p53 / PUMA ; 

PubMed: 27924057     


The expression of p53 or PUMA by western blotting analysis in HCT-116 cells treated with (left) 20 μM pazopanib for indicated hours or (right) with 1-20 μM pazopanib for 24 hours.

p-Akt / Akt ; 

PubMed: 27924057     


Akt is inhibited after pazopanib treatment in colon cells. The expression of P-Akt (S473) was detected by western blotting in (A) RKO or HT-29 cells after 20 μM pazopanib treatment for indicated times.

27924057
Growth inhibition assay
Cell viability; 

PubMed: 27924057     


Cell viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after 1, 5, 10, or 20 μM pazopanib treatment in HCT-116 cells. Data represent the mean ± SEM of four independent experiments.

27924057
体内試験 The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

お薦めの試験操作(参考用のみ)

動物試験:

[2]

- 合併
  • 動物モデル: Immunodeficient mice bearing SYO-1 cells
  • 製剤: --
  • 投薬量: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • 投与方法: Oral administration
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 87 mg/mL (198.84 mM) warming
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 437.52
化学式

C21H23N7O2S

CAS No. 444731-52-6
保管
in solvent
別名 GW786034
Smiles C[N]1N=C2C=C(C=CC2=C1C)N(C)C3=NC(=NC=C3)NC4=CC=C(C)C(=C4)[S](N)(=O)=O

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03735758 Recruiting Drug: pazopanib or guideline conform chemotherapy Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03334409 Recruiting Drug: Ascorbic Acid|Drug: Pazopanib Hydrochloride Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7|Unresectable Renal Cell Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2
NCT03149120 Withdrawn Biological: Nivolumab|Drug: Pazopanib Soft Tissue Sarcomas NYU Langone Health|Bristol-Myers Squibb August 2017 Phase 2
NCT02979899 Completed Biological: TRC105|Drug: Votrient Advanced Angiosarcoma Tracon Pharmaceuticals Inc. February 13 2017 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

VEGFRシグナル伝達経路

相関VEGFR製品

Tags: Pazopanibを買う | Pazopanib ic50 | Pazopanib供給者 | Pazopanibを購入する | Pazopanib費用 | Pazopanib生産者 | オーダーPazopanib | Pazopanib化学構造 | Pazopanib分子量 | Pazopanib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID